BIO-Europe Spring 2019: Apeiron CEO On Pipeline Progress And Partnering
Executive Summary
Peter Llewellyn-Davies, CEO and chief financial officer of Apeiron Biologics, talks to Lucie Ellis, executive editor of In Vivo, on the sidelines of the recent BIO-Europe Spring conference about the company’s pipeline and partnering strategy.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.